Discover Novartis' FDA approval for Lutathera in pediatric patients with GEP-NETs, marking a pivotal milestone in treating this rare cancer. Explore its efficacy in combating SSTR+ tumors, backed ...

Lutathera came to Novartis by way of its acquisition of Advanced Accelerator Applications. Netter-1 tested it in patients with well-differentiated, or G1, tumors.

Novartis has stumbled with a couple of its recent cancer launches, namely the complicated CAR-T rollout for Kymriah and come-from-behind Kisqali debut. But not so with Lutathera.

In the Phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly extended median PFS to 22.8 months vs. 8.5 months with high-dose octreotide LAR in patients with newly diagnosed grade ...

EAST HANOVER, N.J., June 3, 2021 /PRNewswire/ — Novartis today reported the final analysis from the NETTER-1 phase III study comparing treatment using Lutathera(R) (INN: lutetium (177Lu ...

Phase 3 trial results showed Lutathera cut the risk of disease progression or death by 72% as initial treatment for gastroenteropancreatic neuroendocrine tumors, or GEP-NETs.

Novartis AG has agreed to acquire Advanced Accelerator Applications SA for $3.9 billion, a deal that would boost its oncology portfolio as generic competition eats into sales of blockbuster blood ...

Novartis AG (NYSE: NVS) released topline data from the Phase 3 NETTER-2 trial with Lutathera, a radioligand therapy (RLT) for advanced gastroenteropancreatic ...

Novartis is temporarily suspending production of Lutathera and Pluvicto over “potential quality issues identified in its manufacturing processes,” it said May 5. 1. The company did not specify ...

Basel, June 3, 2021— Novartis today reported the final analysis from the NETTER-1 phase III study comparing treatment using Lutathera ® plus 30 mg octreotide LAR to 60 mg of octreotide LAR in ...